유방암 환자 case 리뷰, 처방 토대, 약물치료, SOAP, PHARM note 형식 발표

목차

1. About Brest Cancer
2. Subjective
3. Objective
4. Assessment
5. Plan
6. Question & Answer

본문내용

01 Anatomy

<그 림>

02 Risk factor
Age
Sex
Radiation exposure
Alcohol, life style
Obesity
Estrogen exposure
Genetics
Personal/Family history of cancer

03 Pathologic type
1. Non invasive carcinoma(in situ)
Ductal carcinoma in situ(DCIS)
Lobular carcinoma in situ(LCIS)

2. Invasive carcinoma
Invasive Ductal carcinoma- ~75% of all breast cancer
Invasive Lobular carcinoma- 5~10% of Invasive Breast cancer

<중 략>

01. Pharmaceutical therapy
<'NCCN Guidelines Ver.2.2015>
Treatment for locally Advanced, Non-inflammatory Breast Cancer(Stage 3)

참고 자료

약물치료학(pharmacotherapy, 한국임상약학회, 2015)
NCCN Guidelines Version 2.2015 Invasive Breast Caner (adjuvant endocrine therapy)
Mammogram Interpretation, tuan doan, devin rottiers, (http://www.cancer.gov/cancertopics/factsheet/detection/mammograms)
http://nursingcrib.com/anatomy-and-physiology/anatomy-and-physiology-of-mammary-glands-breast/
Henderson I, Berry D, Demetri G, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;
Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer : first report of intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.1 J Clin Oncol 2003;
Albain KS, Barlow WE, Ravdin PM, et al. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine responsive, node positive breast cancer, Lancer 2009;